News | Stents | January 25, 2018

Elixir Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

Elixir reveals new category of ‘Bioadaptive Drug Eluting Stents’ (BA- DES), sharing DynamX technology, preclinical data, and clinical program at 29th Transcatheter Cardiovascular Therapeutics Conference

 

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, unveiled for the first time its novel stent technology, DynamXTM, a bioadaptive drug-eluting stent (BA-DES) platform at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver.

DynamX, a 71 microns thin cobalt-chromium DES coated with a thin, biodegradable polymer coating that releases Novolimus, an anti-proliferative and anti-inflammatory, is the first of its kind in its ability to allow the vessel to resume arterial pulsatile motion and the Glagovian phenomenon of adaptive remodeling which are both essential for slowing disease progression and minimizing clinical events. Adaptive segments in the stent are held intact by the thin biodegradable polymer coating designed to absorb in six months allowing the adaptive segments to uncage the stent and restore the natural pulsatile motion and adaptive remodeling of the artery.

Current DES permanently cages the artery, causing geometric distortion and stresses that contribute to fractures in approximately 20 percent of stents implanted leading to clinical events. DynamX demonstrated significantly improved conformability, and reduced torsional and longitudinal stresses compared to current DES, thereby reducing geometric distortion of arteries and the potential for stent fractures and clinical events.

“The acute performance of DynamX matched the best in class DES,” said Professor Stefan Verheye, M.D., Ph.D., Antwerp, Belgium.

“I am very excited about the potential of DynamX leading PCI to the next frontier,” said Verheye.

Verheye presented DynamX’s clinical program overview at the TCT conference and was joined by a distinguished panel of faculty Co-Chairs: Martin Leon, Dean Kereiakes and Roxana Mehran.

In addition to launching a new genre of bioadaptive drug-eluting stents with DynamX, Elixir also continues to make advances with its bioresorbable scaffold programs, DESolve CX and DESolve NXT. DESolve’s ability to degrade in six months and nearly completely resorb in one year, while demonstrating positive adaptive remodeling at six-month follow-up have all been affirmations of their respective proprietary technologies and the promising future of the category.

“Elixir is committed to lead the industry to a new and exciting era with its bio-adaptive DynamX DES,” said Motasim Sirhan, CEO of Elixir Medical Corporation. “Elixir is executing on a two-pronged strategy with BRS and BA-DES to develop innovative, adaptive remodeling technologies designed to restore the normal function of arteries.”

For more information: www.elixirmedical.com

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init